A subunit cytomegalovirus vaccine based on recombinant envelope glycoprotein B and a new adjuvant

Journal of Infectious Diseases

Volumn 180, Issue 4, 1999, Pages 970-975

  Pass, Robert F ^a,d   Duliegè, Anne Marie ^b   Boppana, Suresh ^a   Sekulovich, Rose ^b   Percell, Sandra ^b   Britt, William ^a   Burke, Rae Lyn ^b,c  

^a University of Alabama at Birmingham   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c Biotechnology Solutions   (United States)

^d University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOLOGICAL ADJUVANT; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINYLALANYL DIPALMITOYLPHOSPHATIDYLETHANOLAMINE; RECOMBINANT PROTEIN; VIRUS ENVELOPE PROTEIN; VIRUS VACCINE;

ADULT; ANTIBODY RESPONSE; ARTHRALGIA; ARTICLE; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALIC INCLUSION BODY DISEASE; CYTOMEGALOVIRUS; DOUBLE BLIND PROCEDURE; DRUG SAFETY; FEMALE; FEVER; HEADACHE; HUMAN; INJECTION PAIN; MALAISE; MALE; MYALGIA; NAUSEA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; VACCINATION; VACCINE PRODUCTION;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; ANTIBODIES, VIRAL; ANTIBODY FORMATION; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUTRALIZATION TESTS; TIME FACTORS; VACCINES, SYNTHETIC; VIRAL ENVELOPE PROTEINS; VIRAL VACCINES;

EID: 0033370693     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/315022     Document Type: Article

References (21)

1. Pass RE. Immunization strategy for prevention of congenital CMV infection. Infect Agents Dis 1996;5:240-4.
2. Fowler KB, Stagno S, Pass, RF, Britt WJ, Boll TJ, Alford CA. The outcome of congenital cytomegalovirus infection in relation to maternal antibody status, N Engl J Med 1992;326:663-7.
3. Elek SD, Stern H. Development of a vaccine against mental retardation caused by cytomegalovirus infection in utero. Lancet 1974;1:1-5.
4. Plotkin SA, Higgins R, Kurtz JB, et al. Multicenter trial of Towne strain attenuated virus vaccine in seronegative renal transplant recipients, Transplantation 1994;58:1176-8.
5. Britt WJ, Mach M. Human cytomegalovirus glycoproteins, Intervirology 1996;39:401-12.
6. Britt WJ. Neutralizing antibodies detect a disulfide-linked glycoprotein complex within the envelope of human cytomegalovirus. Virology 1984;135:369-78.
7. Britt WJ, Vugler L, Butfiloski EJ, Stephens EB. Cell surface expression of human cytomegalovirus (HCMV) gp55-116 (gB): use of HCMV-vaccinia recombinant virus infected cells in analysis of the human neutralizing antibody response. J Virol 1990;64:1079-85.
8. Spaete RR. A recombinant, subunit vaccine approach to HCMV vaccine development. Transplant Proc 1991;23:90-6.
9. Ott G, Barchfeld GL, Chernoff D, Radhakrishnan R, van Hoogevest P, Van Nest G. MF59. Design and evaluation of a safe and potent adjuvant for human vaccines. In: Powell MF, Newman MJ, eds. Vaccine design: the subunit and adjuvant approach. New York: Plenum Press, 1995:277-296.
10. Adler SP, Starr SE, Plotkin SA, et al. Immunity induced by primary human cytomegalovirus infection protects against secondary infection among women of childbearing age. J Infect Dis 1995;171:26-32.
11. Hicks T, Fowler K, Richardson M, Dahle A, Adams L, Pass R. Congenital cytomegalovirus infection and neonatal auditory screening. J Pediatr 1993;123:779-82.
12. Drew WL, Sweet ES, Miner RC, Mocarski ES. Multiple infections by cytomegalovirus in patients with acquired immune deficiency syndrome: documentation by Southern blot hybridization. J Infect Dis 1984;150:952-3.
13. Chou S. Acquisition of donor strains of cytomegalovirus by renal-transplant recipients. N Engl J Med 1986;314:1418-23.
14. Chandler SH, Handsfield HH, McDougall JK. Isolation of multiple strains of cytomegalovirus from women attending a clinic for sexually transmitted diseases. J Infect Dis 1987;155:655-60.
15. Stagno S, Reynolds DW, Huang ES, Thames SD, Smith RJ, Alford CA. Congenital cytomegalovirus infection: occurrence in an immune population, N Engl J Med 1997;296:1254-8.
16. Bale JF, Petheram SJ, Inara ES, Murph JR. Cytomegalovirus reinfection in young children. J Pediatr 1996;128:347-52.
17. Stagno S, Pass RF, Dworsky ME, et al. Congenital cytomegalovirus infection: the relative importance of primary and recurrent maternal infection. N Engl J Med 1982;306:945-9.
18. Urban M, Klein M, Britt WJ, Hassfurther E, Mach M. Glycoprotein H of human cytomegalovirus is a major antigen for the neutralizing humoral immune response, J Gen Virol 1996;77:1537-47.
19. Li C, Yang X, Tu W, Riddell SR. Human cytomegalovirus matrix protein PP150 is efficiently presented as one of target antigens for cytotoxic T lymphocyte recognition. Chin Med J 1997;110:397-400.
20. Wills MR, Carmichael AJ, Mynard K, et al. The human cytotoxic T lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp65: frequency, specificity and T-cell receptor usage of pp65-specific CTL. J Virol 1996;70:7569-79.
21. Wang JB, Adler SP, Hempfling S, et al. Mucosal antibodies to human cytomegalovirus glycoprotein B occur following both natural infection and immunization with human cytomegalovirus vaccines, J Infect Dis 1996;174:387-92.